A new triple-action weekly injection, retatrutide, has demonstrated significant reductions in blood sugar and body weight during phase 3 clinical trials.
The study was published in the Lancet
Jun 08, 2026
05:20 pm
What's the storyA new triple-action jab for type 2 diabetes has shown promising results in a phase 3 trial.
The study, published in the Lancet, found that patients receiving weekly retatrutide injections for 40 weeks lost over four times as much weight as those on placebo.
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests needed
New weekly diabetes jab retatrutide cuts blood sugar and drives double-digit weight loss in type 2 diabetes patients in major…
But its key advantage is in its weight reduction abilities
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity,…
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an…
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body…
Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide
